| Huang, Jian |
NCT05131841: Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC |
|
|
| Recruiting | 4 | 60 | RoW | Cipterbin Combined With Vinorelbine | Zhejiang Cancer Hospital, Proswell Medical Corporation | Metastatic Breast Cancer | 12/22 | 12/22 | | |
NCT05600322: Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer |
|
|
| Completed | 3 | 158 | RoW | Hexaminolevulinate Hydrochloride, Hexvix, Richard Wolf Photodynamic Diagnostic Equipment (PDD) system, System Blue | Photocure, Jiangsu Yahong Meditech Co., Ltd aka Asieris, Richard Wolf GmbH, Tigermed-Jyton Co., Ltd. | Bladder Cancer | 07/23 | 07/23 | | |
NCT06241755: Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC) |
|
|
| Recruiting | 3 | 412 | RoW | BCG for Therapeutic Use, BCG | Chengdu CoenBiotech Co., Ltd, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Non-Muscle Invasive Bladder Cancer | 09/25 | 09/26 | | |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 02/25 | 08/28 | | |
NCT04799847: Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine |
|
|
| Recruiting | 1/2 | 161 | RoW | Catumaxomab | LintonPharm Co.,Ltd. | Bladder Cancer | 11/24 | 11/24 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
NCT06001580: A Phase I Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | BR101 | Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd | Advanced Solid Tumor | 12/23 | 06/26 | | |
NCT06672263: A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia |
|
|
| Not yet recruiting | 1 | 120 | RoW | TQB3911 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Chronic Myelogenous Leukemia | 09/26 | 12/26 | | |
NCT04948528: Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for Upper Tract Urothelial Carcinoma Detection |
|
|
| Recruiting | N/A | 490 | RoW | Active Comparator: Surgery Pathology or Cystoscopy, Active Comparator: Clinical Diagnosis | AnchorDx Medical Co., Ltd., Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Peking University First Hospital, Peking University Third Hospital, Peking Union Medical College Hospital, The Affiliated Hospital of Qingdao University, First Affiliated Hospital, Sun Yat-Sen University, Sir Run Run Shaw Hospital, The First Affiliated Hospital of Zhengzhou University | Upper Tract Urothelial Carcinoma | 06/23 | 12/23 | | |
| Chen, Dan |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 02/25 | 08/28 | | |
| Renwick, William |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 02/25 | 08/28 | | |
| Xu, Jian |
NCT05830500: Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma |
|
|
| Recruiting | 4 | 360 | RoW | Anlotinib Hydrochloride Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Medullary Thyroid Cancer | 06/27 | 12/28 | | |
| Recruiting | 2/3 | 240 | Europe, Canada, Japan, US, RoW | EFG PH20 SC, PBO | argenx, argenx BV | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | 12/26 | 02/27 | | |
| Recruiting | 2 | 146 | RoW | Sirolimus, rapamycin, Placebo | Chinese SLE Treatment And Research Group, Beijing Municipal Science & Technology Commission, North China Pharmaceutical Group Corporation | Systemic Lupus Erythematosus | 10/24 | 05/25 | | |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
NCT05227677: Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 200 | RoW | GA guided anti-diabetic therapy adjustment, current guidelines to adjust treatment | Asahi Kasei Pharma Corporation | Type 2 Diabetes Mellitus | 08/24 | 12/24 | | |
| Liu, Lunfei |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT06173284: Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 510 | RoW | 611, Matching placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic | 09/25 | 05/26 | | |
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 430 | RoW | Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid | Eli Lilly and Company | Atopic Dermatitis | 12/25 | 11/26 | | |
| Recruiting | 3 | 189 | RoW | Roflumilast Cream 0.3%, Zoryve, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Plaque Psoriasis | 06/25 | 07/25 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
| Completed | 2 | 93 | RoW | 611 Q2W, 611 Q4W, Matching placebo, placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic | 07/23 | 09/23 | | |
| Recruiting | 2 | 159 | Europe, Canada, Japan, US, RoW | GSK1070806 | GlaxoSmithKline | Dermatitis, Atopic | 11/29 | 11/29 | | |
NCT05999799: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 199 | Europe, Canada, Japan, US, RoW | GSK1070806, Placebo | GlaxoSmithKline | Dermatitis, Atopic | 10/25 | 01/26 | | |
| Zhu, Yuefeng |
NCT05899478: Suture-mediated Closure System Following Endovascular Peripheral Arterial Procedures |
|
|
| Not yet recruiting | N/A | 136 | RoW | Tyknot® Suture-Mediated Closure System, Perclose® ProGlide Suture-Mediated Closure System | Suzhou Hengruihongyuan Medical Technology Co. LTD | Percutaneous Intervention Via Femoral Artery | 03/24 | 05/24 | | |
| Xu, Jiang |
NCT05701644: Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects |
|
|
| Completed | 1 | 36 | RoW | C1K 150mg, C1K 300mg, Placebo with the same volume of C1K 300mg, C1K 600mg, Placebo with the same volume of C1K 600mg, C1K 900mg, Placebo with the same volume of C1K 900mg, C1K 1200mg, Placebo with the same volume of C1K 1200mg | Ensol Bioscience | Healthy | 06/23 | 06/23 | | |
| Zheng, Yichun |
| No trials found |
| Zhuang, Genying |
| No trials found |
